This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

By: Adam Feuerstein | 07/23/14 - 05:44 PM EDT

Updated with new information following Gilead's conference call:

Gilead Sciences (GILD) just reported second-quarter Sovaldi sales of $3.48 billion, a tad short of the buyside investor "whisper number" consensus of $3.5 billion. (But a lot lower than the "whisper whisper" consensus of $4 billion.)

In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable, but Wall Street had high expectations for the drug going into tonight's earnings announcement. We'll soon see how traders react to the news. Gilead shares closed Wednesday at $90.34 in front of the second-quarter earnings announcement. 

Update: Gilead is down less than 1% to $89.70 in Wednesday's after-market trading session.

Overall, Gilead reported second-quarter adjusted earnings of $2.36 per share. Total revenue was $6.54 billion. Both the top- and bottom-line performance bested sell-side consensus forecasts, but that's not a surprise at all because analysts had been woefully under-counting Sovaldi sales for the quarter.

Gilead provided new guidance for 2014 total product sales of $21-23 billion, which includes Sovaldi sales for the first time. (Previous company guidance excluded Sovaldi.)

At the end of the second quarter, Gilead's cash pile stood at $9.58 billion. What is the company going to do with all that money? 

Update: More than 9,000 hepatitis C patients have been cured following Sovaldi treatment, the company said. More than 80,000 hepatitis C patients have initiated Sovaldi treatment since the drug's launch. 

Gilead President John Milligan described the Sovaldi pricing controversy as a "lively debate," and said progress is being made with Medicaid providers on reimbursement. He later added, "Some people consider Sovaldi an 'outlier' because we are curing people of a horrible disease in record time." Zing! 

On the R&D front, Gilead expects results later this quarter from phase III studies of TAF, the follow-on, improved version of the HIV drug Viread. This is an important clinical catalyst for the company's still-strong, core HIV franchise. 

Gilead repurchased $1.2 billion of its own stock (15.2 million shares) in the second quarter at an average price of $79.07. Another $5 billion share repurchase program has been authorized. The company continues to see share repurchases as a better use of cash over starting a dividend program. 




Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 17,055.87 -116.81 -0.68%
S&P 500 1,982.77 -11.52 -0.58%
NASDAQ 4,508.6880 -19.0010 -0.42%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs